Flow Space on MSN
Prostate cancer progression: What caregivers need to know
Fear can take over the moment prostate cancer progresses. These questions can help caregivers replace confusion with clarity, ...
A research team at Kanazawa University, led by Professor Atsushi Mizokami, Associate Professor Koji Izumi and Specially ...
11hon MSN
This aggressive prostate cancer finally has targeted treatment — AstraZeneca wins FDA nod
AstraZeneca Plc AZN received two significant regulatory updates from the U.S. Food and Drug Administration, with its cancer ...
Active surveillance is a standard approach for managing men with low‑risk prostate cancer to help delay or avoid treatment, but a significant number of patients eventually experience disease ...
MedPage Today on MSN
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting
Capivasertib plus abiraterone combination lands indication for PTEN-deficient tum ...
The FDA has approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for men with phosphatase and tensin homolog (PTEN)-deficient metastatic androgen pathway ...
The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...
AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient ...
Men with a particular form of prostate cancer now have a targeted treatment for the first time, thanks to FDA approval of a ...
The FDA has approved capivasertib (Truqap) in combination with abiraterone acetate (Zytiga) and prednisone for adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results